SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00- £17.36m
- £15.72m
- 21
- 12
- 59
- 18
REG - Solvonis Therapeutic - Allowance of U.S. patent covering AI-supported CNS
AnnouncementREG - Solvonis Therapeutic - Initiation of AI supported CNS drug discovery
AnnouncementREG - Solvonis Therapeutic - Synthesis of development candidate for SVN-SDN-014
AnnouncementREG - Solvonis Therapeutic - Notice of Annual General Meeting
AnnouncementREG - Solvonis Therapeutic - Appointment of Prof. David Nutt as CSO
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementRCS - Solvonis Therapeutic - Presentation at Mello2025
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - Completion of the acquisition of Awakn
AnnouncementREG - Solvonis Therapeutic - Publication of a Prospectus
AnnouncementREG - Solvonis Therapeutic - Result of placing
AnnouncementREG - Solvonis Therapeutic - Proposed equity fundraising via ABB
AnnouncementREG - Solvonis Therapeutic - Result of General Meeting
AnnouncementREG - Solvonis Therapeutic - Proposed acquisition of Awakn approved
AnnouncementREG - Solvonis Therapeutic - Final Results for the year ended 31 December 2024
Announcement